RxDoctor Payments Data

Huamin Li, MD

Allergy · Wheaton, MDNPI 1396733291

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $376,947 of the $575,722 with a category attached, or 65.5%. 36 manufacturers reported payments, led by CSL Behring at 42.7% of the total. Among allergy clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$575,722in general payments, 2019–2025

Across 1,229 payments — averaging $468.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$246K
  • Pharming Healthcare, Inc.$125K
  • Biocryst US Sales Co., LLC$73K
  • Shire North American Group Inc$49K
  • Biocryst Pharmaceuticals, Inc.$26K
  • ARS Pharmaceuticals Operations, Inc.$15K
  • plus $42K from 30 others
$1,022,926in research payments, 2019–2025

Across 319 payments — averaging $3206.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$361K
  • Takeda Pharmaceuticals U.S.A., Inc.$206K
  • Biocryst Pharmaceuticals, Inc.$144K
  • Shire North American Group Inc$101K
  • Amgen$71K
  • Pfizer$64K
  • plus $77K from 5 others
$18,119in ownership & investment interests, 2019–2025

Across 2 payments — averaging $9059.38 each. An ownership or investment interest held by the physician or an immediate family member.

  • Consortium Of Independent Immunology Clinics, LLC$18K

What the payments were for

  • Consulting fees$117,90020%
  • Speaking & faculty fees$376,94765%
  • Travel & lodging$50,3639%
  • Food & beverage$30,3875%
  • Education$1250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$575,722 in reported general payments places this provider in the 95th percentile of 29 allergy providers in Maryland.

See all allergy providers in Maryland

Medicare billing

Part B allowed, 2024
$1,113,448
Medicare patients
395
Services billed
30,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab21$98,694
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$22,772
Arnuity ElliptaFluticasone Furoate30$9,113
Mometasone Furoate15$1,533
Azelastine Hcl28$1,523
Clarithromycin20$1,484
Ipratropium Bromide18$1,306
Azelastine-FluticasoneAzelastine/Fluticasone11$1,244
Albuterol Sulfate HfaAlbuterol Sulfate35$933
Montelukast Sodium31$549
Gabapentin15$229
Azithromycin17$145
Prednisone11$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta$1,028$31,88545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 29 allergy providers in Maryland.

Other allergy in Wheaton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →